Crenigacestat – 10 mg

Brand:
Cayman
CAS:
1421438-81-4
Storage:
-20
UN-No:
Non-Hazardous - /

Crenigacestat is an orally bioavailable Notch inhibitor.{53344} It induces cell cycle arrest at the G0/G1 phase and decreases expression of the oncogenes MYC and CCNA1 in Caki human renal cancer cells.{35883} Crenigacestat (8 mg/kg per day) reduces tumor growth and increases survival in a 769-P mouse xenograft model.  

 

Available on backorder

SKU: 27919 - 10 mg Category:

Description

A Notch inhibitor; induces cell cycle arrest at the G0/G1 phase and decreases MYC and CCNA1 expression in Caki human renal cancer cells; reduces tumor growth and increases survival in a 769-P mouse xenograft model at 8 mg/kg per day


Formal name: N-[(1S)-2-[[(7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-butanamide

Synonyms:  LY3039478

Molecular weight: 464.4

CAS: 1421438-81-4

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cancer|Cell Cycle||Research Area|Cell Biology|Cell Signaling|Notch Signaling